Onco-Innovations' Private Placement Fully Subscribed
Summary
Closing of the Private Placement is expected to occur on or about January 31, 2025.The Company has received overwhelming interest from the market, which it believes reflects the strong confidence investors have in Onco-Innovations and its vision. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Oncos commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.For more information, please contact:Thomas OShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@oncoinnovations.comThe CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.Forward-Looking Statements Caution. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to complete the Private Placement as contemplated, or at all, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.